Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study.

Furthermore, within the CIBP group, patients with PD-L1 expression ≥1% showed a trend towards longer PFS (HR 0.64, 95% CI: 0.41-1.00) and OS (HR 0.68, 95% CI: 0.40-1.15) compared to those with PD-L1 <1%, although these differences were not statistically significant ( Supplementary Figure 2 ). 3.3 Cox regression To ascertain the independent prognostic value of the CIBP strategy, we performed univariable and multivariable Cox regression analyses.

also in 53,322 other papers